Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | HEXA | P06865 | 1/20 | 0.31 |
| ▸ | HEXB | P07686 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25191860 | 0.89 | ADORA2B (0.35) | CYP3A4TDP1RXRAADORA2B | |
| SCHEMBL30976972 | 0.87 | GSK3B (0.41) | ADORA2B | |
| SCHEMBL24650044 | 0.87 | CYP3A4 (0.33) | CYP3A4TDP1 | |
| SCHEMBL8510636 | 0.81 | TDP1 (0.37) | CYP3A4TDP1RXRASMN1; SMN2HEXA | |
| SCHEMBL5198850 | 0.81 | APEX1 (0.54) | CYP3A4SMN1; SMN2APEX1 | |
| SCHEMBL21986055 | 0.81 | NPSR1 (0.58) | NPSR1SMN1; SMN2 | |
| SCHEMBL4965040 | 0.77 | CA12 (0.42) | TDP1RXRA | |
| SCHEMBL25194183 | 0.73 | PIM1 (0.34) | TDP1RXRAHEXAHEXBAPEX1 | |
| SCHEMBL5199211 | 0.69 | APEX1 (0.34) | SMN1; SMN2APEX1 | |
| SCHEMBL11264592 | 0.69 | ALDH1A1 (0.54) | TDP1RXRANPSR1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161379-A | Intumescent nitrogen-phosphorus flame retardant and preparation method thereof | 南京林业大学 | 2024-12-20 | — | — | CN | claimed |
| US-20260144748-A1 | POLYOL-BASED MULTI-FUNCTIONAL COMPOUNDS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260144900-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH GOLD NANOPARTICLES FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260020859-A1 | MATERIALS FOR CONFORMABLE FILLABLE MEDICAL BALLOONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260021223-A1 | HYDROGEL FILLERS FOR CONFORMABLE FILLABLE MEDICAL BALLOONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250332292-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025226800-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250248935-A1 | SYSTEMS AND METHODS FOR ON-DEMAND CLEAVAGE OF HYDROGELS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250059237-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-119161379-A | Intumescent nitrogen-phosphorus flame retardant and preparation method thereof | 南京林业大学 | 2024-12-20 | — | — | CN | disclosed |
| EP-1352921-B1 | EXTRUDED STYRENE RESIN FOAM AND PROCESS FOR PRODUCING THE SAME | KANEKA CORP (JP) | 2007-02-14 | — | — | EP | disclosed |
| EP-1752486-A1 | Extruded styrene resin foam and process for producing the same | Kaneka Corporation (JP) | 2007-02-14 | — | — | EP | disclosed |
| US-6841581-B2 | Extruded styrene resin foam and process for producing the same | KANEKA CORPORATION (JP) | 2005-01-11 | — | — | US | disclosed |
| US-20030220408-A1 | Extruded styrene resin foam and process for producing the same | KANEKA CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1352921-A1 | EXTRUDED STYRENE RESIN FOAM AND PROCESS FOR PRODUCING THE SAME | KANEKA CORPORATION (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-4806574-A | Ultraviolet curable coatings for optical glass fiber based on a polyfunctional core | DESOTO, INC. (US) | 1989-02-21 | — | — | US | disclosed |
| US-4728697-A | DIELECTRIC COATINGS FOR METAL CONDUCTORS | GENERAL ELECTRIC COMPANY (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0223958-A2 | Crosslinked copolyamideimides and method for their preparation | GENERAL ELECTRIC COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
| EP-0209641-A2 | Ultraviolet curable coatings for optical glass fiber base on a polyfunctional core | DeSOTO, INC. (US) | 1987-01-28 | — | — | EP | disclosed |
| US-4543376-A | AS A BINDER A MIXTURE OF A POLYADDUCT, POLYCONDENSATE, OR HYDROXYL OR AMINE-CONTAINING POLYMER, AND A POLYAMINE-CYCLIC CARBONIC ACID ESTER REACTION PRODUCT | BASF AKTIENGESELLSCHAFT (DE) | 1985-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332292-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS | CD44, CRYAA, ILK | CYP3A4 3900/4885TDP1 991/4885RXRA 1793/4885 |
| US-20250248935-A1 | SYSTEMS AND METHODS FOR ON-DEMAND CLEAVAGE OF HYDROGELS | PLG, FGB, ADAM33 | CYP3A4 3580/4885TDP1 276/4885RXRA 2940/4885 |
| US-20250059237-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM | HDGF, IAPP, QRFPR | CYP3A4 4803/4885TDP1 3211/4885RXRA 1567/4885 |
| US-20260021223-A1 | HYDROGEL FILLERS FOR CONFORMABLE FILLABLE MEDICAL BALLOONS | H1-5, H1-2, H1-3 | CYP3A4 3136/4885TDP1 3701/4885RXRA 2382/4885 |
| US-20260020859-A1 | MATERIALS FOR CONFORMABLE FILLABLE MEDICAL BALLOONS | SMCHD1, KDM8, H1-5 | CYP3A4 2149/4885TDP1 3816/4885RXRA 1994/4885 |
| US-20260144900-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH GOLD NANOPARTICLES FOR MEDICAL APPLICATIONS | KLK3, BPHL, BRDT | CYP3A4 2379/4885TDP1 2922/4885RXRA 3093/4885 |
| US-20260144748-A1 | POLYOL-BASED MULTI-FUNCTIONAL COMPOUNDS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME | CD44, PAM, PLOD3 | CYP3A4 2002/4885TDP1 3513/4885RXRA 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.